AKT1 and non-small cell lung carcinoma: Among them, compounds #2 (Figure S1A–E), #40 (Figure 2A–D and Figure S1F), #51 (Figure 2A–D) and #19 (Figure 2E and Figure S1G–I) showed effects in suppressing the Akt-pS473 signal in at least three out of four NSCLC lines tested in both compound dose- (Figure S1D,F–I) and time- (Figure S1E) dependent manners.